| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.24M | 35.58M | 20.76M | 31.10M | 45.78M | 33.20M |
| Gross Profit | 30.42M | 35.58M | 13.02M | 23.52M | 42.88M | -45.24M |
| EBITDA | -112.50M | -103.37M | -122.10M | -124.28M | -78.84M | -62.89M |
| Net Income | -111.58M | -105.32M | -132.49M | -128.18M | -83.89M | -66.33M |
Balance Sheet | ||||||
| Total Assets | 296.53M | 349.60M | 376.45M | 430.84M | 506.76M | 400.14M |
| Cash, Cash Equivalents and Short-Term Investments | 214.55M | 244.90M | 253.68M | 276.15M | 309.28M | 371.69M |
| Total Debt | 62.92M | 65.76M | 70.98M | 87.15M | 42.88M | 22.92M |
| Total Liabilities | 122.46M | 133.62M | 130.34M | 141.61M | 117.16M | 119.35M |
| Stockholders Equity | 174.06M | 215.99M | 246.11M | 289.23M | 389.61M | 280.79M |
Cash Flow | ||||||
| Free Cash Flow | -87.58M | -65.34M | -108.55M | -111.44M | -88.24M | -67.90M |
| Operating Cash Flow | -87.41M | -65.16M | -106.84M | -105.94M | -86.97M | -67.25M |
| Investing Cash Flow | 81.88M | -51.27M | 158.35M | 58.42M | -189.34M | -190.50M |
| Financing Cash Flow | 10.57M | 45.34M | 45.49M | 1.15M | 171.40M | 348.93M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $221.50M | ― | -52.99% | ― | 16.55% | 16.73% | |
43 Neutral | $248.91M | ― | -180.71% | ― | ― | 64.43% | |
42 Neutral | $156.27M | -2.25 | ― | ― | -100.00% | 66.57% | |
35 Underperform | $208.39M | ― | -16.20% | ― | ― | ― | |
33 Underperform | $138.01M | ― | ― | ― | ― | -406.67% |
On October 16, 2025, C4 Therapeutics announced an underwritten offering of common stock and warrants, expected to close on October 17, 2025. The company anticipates net proceeds of approximately $117 million, extending its cash runway to the end of 2028, with potential total proceeds reaching $341.7 million if all warrants are exercised.
The most recent analyst rating on (CCCC) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.
On October 16, 2025, C4 Therapeutics announced the presentation of data from its Phase 1 clinical trial of cemsidomide combined with dexamethasone for relapsed/refractory multiple myeloma, highlighting its potential efficacy and safety profile. Additionally, the company terminated a sales agreement prospectus with TD Securities, impacting its stock sale strategy, while maintaining the agreement’s validity for future use, having previously raised approximately $9.6 million through stock sales.
The most recent analyst rating on (CCCC) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.
On October 1, 2025, C4 Therapeutics announced a clinical trial collaboration and supply agreement with Pfizer. Under this agreement, Pfizer will provide elranatamab, a BCMAxCD3 bispecific antibody, at no cost for C4T’s upcoming Phase 1b trial. This trial will evaluate the safety and tolerability of cemsidomide, an IKZF1/3 degrader, and dexamethasone in combination with elranatamab for treating relapsed/refractory multiple myeloma. The collaboration aims to establish an optimal dose for this combination therapy, potentially improving outcomes for multiple myeloma patients.
The most recent analyst rating on (CCCC) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.
On September 20, 2025, C4 Therapeutics announced data from its Phase 1 clinical trial of cemsidomide, an IKZF1/3 degrader, in combination with dexamethasone for relapsed/refractory multiple myeloma. The trial showed promising results with a 50% overall response rate at the highest dose level and a differentiated safety profile, supporting further development for potential accelerated approval. The company plans to initiate Phase 2 and Phase 1b studies in 2026, aiming to position cemsidomide as a class-leading treatment option.
The most recent analyst rating on (CCCC) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines through targeted protein degradation, primarily in the oncology sector. The company leverages its proprietary TORPEDO platform to advance its research and development efforts.
On August 7, 2025, C4 Therapeutics announced the completion of enrollment and dose escalation for its Phase 1 trial of cemsidomide in multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL), showing promising response rates. The company plans to align with the FDA on a Phase 2 dose by the end of 2025 and initiate registrational development in early 2026, focusing on MM treatment. Financially, C4T reported a decrease in revenue for Q2 2025 compared to the previous year, primarily due to a previous milestone payment, but maintained a strong cash position expected to fund operations until mid-2027.
The most recent analyst rating on (CCCC) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.